In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...
Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.
3, 4 “The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and ...
Organon (OGN) announced completion of its acquisition of Dermavant Sciencesfrom Roivant (ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions ...
Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...
GlobalData on MSN15d
Dermavant acquisition expands Organon’s dermatology portfolioOrganon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.
“The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback